Overview

Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

Status:
NOT_YET_RECRUITING

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

This is an open-label, single-arm, pharmacokinetic and safety study of Likmez in pediatric patients aged 12 months to \<4 years with anaerobic bacterial infection

Phase:

PHASE2

Details

Lead Sponsor:

Saptalis Pharmaceuticals LLC

Collaborator:

CBCC Global Research

Treatments:

Metronidazole
Suspensions